Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging

NCT ID: NCT02787356

Last Updated: 2017-10-09

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-01
• Study Completion Date: 2017-12-31

Brief Summary

The purpose of this study is to (1) collect trained observer scores and digital images of skin irritated by generic and RLD Lidocaine 5% delivered via TDS, and (2) assess performance of an automated system for predicting scores directly from the digital images

Detailed Description

Subjects will be screened prior to dosing to ensure subjects meet all inclusion exclusion criteria. The test materials will be tested simultaneously. Skin sites on the paraspinal region will be utilized for application. The test sites will be randomized among the individual subjects according to their assigned identification number. All patches will be applied and removed by the laboratory staff.

Due to safety concerns, it is not recommended to simultaneously apply two whole, active, Lidocaine Patch 5% patches on the same subject during the 21-day period. The optimum design of this study will depend on the design of the test product patch. Since the RLD has a matrix design that can be safely cut, one-fourth of the patch can be used for these studies. If the test product patch also has a design that can be cut to a smaller size, it should also be cut in one-fourth and one-fourth of the test product patch applied simultaneously with one-fourth of a RLD patch (to separate skin sites).

Each test article will be applied to sites on the skin for a contact period of approximately 24 hours (+/-1 hr.), with the exception of the weekend (72 hours, +/- 1 hr.). There will be no visits during the weekend.

Evaluations will be made after removal of every patch by a single trained grader along with a single digital imaging instrument. Re-applications will be made to the same test sites unless reactions become so strong (combination of a number and letter grade of 3) as to make this unadvisable, at which point patch application will be discontinued for that test article.

Conditions

Skin Manifestations

Keywords

Skin Diseases, Erythema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

TDS Lidocaine 5%; generic

TDS Lidocaine 5%; generic with trained skin graders and images of skin

Group Type: EXPERIMENTAL

TDS Lidocaine 5%; generic

Intervention Type: DRUG

TDS Lidocaine 5%; generic

TDS Lidocaine 5%; RLD

TDS Lidocaine 5%; RLD with trained skin graders and images of skin

Group Type: EXPERIMENTAL

TDS Lidocaine 5%; RLD

Intervention Type: DRUG

TDS Lidocaine 5%; RLD

Interventions

TDS Lidocaine 5%; generic

TDS Lidocaine 5%; generic

Intervention Type: DRUG

TDS Lidocaine 5%; RLD

TDS Lidocaine 5%; RLD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males and Females, age [18-65 years old or 18 years or older]
• Signed informed consent
• Good general health

Exclusion Criteria

• Subject is pregnant or lactating.
• Medical history of condition that would significantly influence the immune response (e.g., primary or acquired immunodeficiencies, such as HIV positive or AIDS, allergic diseases, such as anaphylaxis, asthma or generalized drug reaction, neoplasms, such as lymphoma or leukemia, rheumatoid arthritis, or systemic lupus erythematosus).
• Medical history of significant dermatologic diseases or conditions, such as atopy, psoriasis, vitiligo or conditions known to alter skin appearance or physiologic response (e.g. diabetes, porphyria).
• History of significant dermatologic cancers (e.g. melanoma, squamous cell carcinoma), except basal cell carcinomas that were superficial and did not involve the investigative site.
• Medical history of hepatic disease
• Within three weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product (e.g. cyclosporine, tacrolimus, systemic or topical corticosteroids, cytotoxic drugs, immune globulin,
• Bacillus Calmette-Guerin, monoclonal antibodies, radiation therapy).
• Within 72 hours prior to dosing, use of antihistamines or use of topical drugs at patch site.
• Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug.
• Presence of open sores at the application site.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

TKL Research, Inc.

INDUSTRY

Sponsor Role: collaborator

SRI International

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan Dosik, MD

Role: PRINCIPAL_INVESTIGATOR

TKL Research, Inc.

Related Links

http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-16-010.html

Use of Imaging and Digital Image Analysis Software/s to Evaluate Transdermal Irritation and Non - inferiority of Generic Transdermal Products (U01)

Other Identifiers

RFA-FD-16-010-SRI-TKL-002

Identifier Type: -

Identifier Source: org_study_id